HTG MOLECULAR DIAGNOSTICS IN - COM NEW (HTGM)

Q1 2022 13F Holders as of 31 Mar 2022

Type / Class
Equity / COM NEW
Total 13F shares
2,295,110
Share change
-382,432
Total reported value
$3,189,000
Price per share
$1.39
Number of holders
16
Value change
-$3,625,386
Number of buys
8
Number of sells
8

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM NEW (HTGM) as of Q1 2022

As of 31 Mar 2022, HTG MOLECULAR DIAGNOSTICS IN - COM NEW (HTGM) was held by 16 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,295,110 shares. The largest 10 holders included ARMISTICE CAPITAL, LLC, Samjo Capital LLC, Cowen Prime Advisors LLC, Nantahala Capital Management, LLC, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, BlackRock Inc., and MORGAN STANLEY. This page lists 16 institutional shareholders reporting positions in this security for the Q1 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.